Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Pedmark (sodium thiosulfate) is the first med approved to lower risk of hearing loss in children treated with cisplatin chemotherapy.
The study of 273 cancer survivors found that over 50% experienced significant hearing loss and more than 35% reported tinnitus.
A higher dose of cisplatin and combination with other medications influence the development of hearing loss.
Reducing the treatment burden can reduce the risk of serious side effects, some of which can endure for years.
In the study, the antioxidant made children less likely to permanently lose hearing without affecting their chemotherapy treatment.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.